home All News open_in_new Full Article
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing the first set of patients in the TUSCANY Phase 1/2 study […]
today 12 hours ago attach_file Science
attach_file
Other
attach_file
Politics
attach_file
Society
attach_file
Economics
attach_file
Sport
attach_file
Events
attach_file
Culture
attach_file
Technology
attach_file
Science
attach_file
Other
attach_file
Politics
attach_file
Society
attach_file
Economics
attach_file
Sport
attach_file
Culture
attach_file
Other
attach_file
Politics
attach_file
Society
attach_file
Economics
attach_file
Culture
attach_file
Other
attach_file
Politics
attach_file
Economics
attach_file
Culture
attach_file
Other
attach_file
Politics
attach_file
Economics
attach_file
Culture
attach_file
Other
attach_file
Politics
attach_file
Economics
attach_file
Other
attach_file
Politics
attach_file
Economics
attach_file
Politics
attach_file
Economics
ID: 15695310